SCHEMBL20142394

SCHEMBL20142394

CNCC(O)c1ccc(OC(=O)CC(C)C)c(OC(=O)CC(C)C)c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 6/20 0.67
ALDH1A1 P00352 3/20 0.67
CYP3A4 P08684 2/20 0.67
LMNA P02545 2/20 0.67
ADRB2 P07550 6/20 0.66
ALOX15 P16050 2/20 0.52
KDM4E B2RXH2 6/20 0.48
TDP1 Q9NUW8 5/20 0.48
ADRA2A P08913 4/20 0.48
ADRA2C P18825 4/20 0.48
MAPT P10636 3/20 0.48
HSD17B10 Q99714 3/20 0.48
TSHR P16473 3/20 0.48
ADRB1 P08588 3/20 0.48
ADRB3 P13945 3/20 0.48
ADRA2B P18089 3/20 0.48
DRD1 P21728 3/20 0.48
ADRA1A P35348 3/20 0.48
DRD3 P35462 3/20 0.48
MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11529624 0.89 HIF1A (0.64) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL23337952 0.86 HIF1A (0.71) HIF1AALDH1A1CYP3A4LMNAADRB2
Dibutepinephrine SCHEMBL20141839 0.84 HIF1A (0.69) HIF1AALDH1A1CYP3A4LMNAADRB2
Hydrochloric Acid SCHEMBL11287167 0.84 ADRB2 (0.57) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL23318966 0.84 HIF1A (0.72) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL23318973 0.83 HIF1A (0.67) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL20142145 0.83 HIF1A (0.71) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL23397578 0.82 HIF1A (0.74) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL21529463 0.82 HIF1A (0.66) HIF1AALDH1A1CYP3A4LMNAADRB2
SCHEMBL20142113 0.82 HIF1A (0.66) HIF1AALDH1A1CYP3A4LMNAADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11021437-B2 Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof IONO PHARMA, LLC (US) 2021-06-01 US disclosed
US-20190337886-A1 PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE OR A PRO-DRUG THEREOF lono Pharma, LLC (US) 2019-11-07 US disclosed
WO-2018089570-A1 PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE IONO PHARMA, LLC (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190337886-A1 PHARMACEUTICAL FORMULATION FOR SUBLINGUAL OR BUCCAL DELIVERY OF EPINEPHRINE OR A PRO-DRUG THEREOF ADRB3, ADRB1, ADRB2 HIF1A 2251/4885ALDH1A1 1112/4885CYP3A4 70/4885
US-11021437-B2 Pharmaceutical formulation for sublingual or buccal delivery of epinephrine or a pro-drug thereof ADRB3, ADRB1, ADRB2 HIF1A 2251/4885ALDH1A1 1112/4885CYP3A4 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.